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Summary: The effect of phenothiazines (trifluoperazine and chlorpromazine) on cholesteryl ester metabolism
has been investigated in J 774 mouse monocyte-macrophages. The incorporation of oleic acid into cholesteryl
ester and the activity of acylcoenzyme A : cholesterol-O-acyltransferase were strongly decreased in cells
pretreated for 24 h with trifluoperazine or chlorpromazine. Furthermore, trifluoperazine or chlorpromazine
decreased the degradation of acetylated low density lipoprotein by J 774 cells. When cell homogenates were
preincubated in vitro with trifluoperazine or chlorpromazine, a marked inhibition of acylcoenzyme A :
cholesterol-O-acyltransferase activity was observed. In cells incubated with acetylated low density lipoprotein
loaded with radiolabeled cholesteryl-linoleate, trifluoperazine and chlorpromazine dramatically reduced the
radioactivity recovered in cholesteryl esters. The radioactivity recovered in free cholesterol was also decreased,
but to a lesser extent. These results suggest that phenothiazines could efficiently antagonize cholesteryl ester
accumulation in macrophages by at least two different mechanisms: a reduction of modified LDL catabolism,
and a direct inhibition of the enzyme acylcoenzyme A : cholesterol-O-acyltransferase.
Introduction , , , , . , - , , . ^lesteryl esters occurs because modified LDL uptake
Atherosclerotic lesions have been demonstrated to be is not down-regulated (4). This process is currently
infiltrated by foam cells derived from monocyte-mac- believed to be closely involved in the appearance of
rophages overloaded with cholesteryl esters (1). Mah- atherosclerotic lesions (1).
ley et al. (2) and Goldstein et al. (3) reported the
existence of receptors for modified low-density lipo- We previously reported a biphasic effect of phenothi-
proteins (LDL), such as acetylated LDL, at the sur^ azines such as trifluoperazine and chlorpromazine on
face of macrophages, and such receptors have also LDL and sterol metabolism in human fibroblasts (5,
been found in monocytes by Fogelman et al. (4). 6). We demonstrated that these drugs are potent in-
Uptake of modified LDL by monocyte-derived mac- hibitors of cholesterol esterification in fibroblasts (6).
rophages leads to massive accumulation of cholesteryl Such an effect has been also reported for chlorprom-
esters, due to a dramatic increase in acylcoenzyme A azine in another experimental model, the arterial wall,
: cholesterol-O-acyltransferase activity (2—4). Over- by Bell (7, 8). In view of the fact that cholesteryl ester
loading of monocyte-derived macrophages with cho- accumulation is closely involved in atherogenesis, it
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was of interest to investigate the effect of phenothi-
azines on cholesterol esterification in the monocyte-
macrophage. In the present work, we demonstrated a
strong inhibition of cholesteryl ester formation by
trifluoperazine and chlorpromazine in J 774 mouse
monocyte-like cells.
Materials and Methods
Materials
Trifluoperazine and chlorpromazine were from Sigma Chemical
Co., St. Louis, MO, U.S.A. [l-14C]oleic acid 2.11 GBq/mmol,
[l-I4C]oleoyl Coenzyme A 2.11 GBq/mmol and 125INa 481 GBq/
mg were from Amersham, Buckinghamshire, U. K. [cholesteryl-
l,2,6,7-3H(N)]cholesteryl linoleate 3704 GBq/mmol was from
New England Nuclear, Boston, U.S.A. Dulbecco modified
Minimum Essential Medium with Earle's salts and foetal calf
serum were from Gibco, Grand Island, NY, U.S.A.; Ultroser
G from Industries Biologiques Frangaises, Villeneuve la Gar-
enne, France; J 774 mouse macrophages from the American
Type Culture Collection, Camden, New Jersey, U. S. A. Silica
gel plates F 1500 were from Schleicher and Schuell, Dassel,
W.-Germany. , ,
Cell cul ture
J 774 cells were cultured in 35 mm Nunc Petri dishes containing
1 ml Dulbecco MEM medium supplemented with 20 mmol
Hepes buffer (pH 7.4), penicillin, streptomycin, and foetal calf
serum, volume fraction 0.1, at 37 °C in a humidified atmosphere
of 5% CO2 95% air. For experiments, foetal calf serum was
replaced by 2% Ultroser G and 50 mg/1 acetylated-LDL for
induction of acylcoenzyme A : cholesterol-O-acyltransferase.
LDL preparation and acetylation
LDL was prepared from normal human serum by 3 step ultra-
centrifugation at 105 000 g in a L5-50 Beckman instrument,
according to Havel el al. (9). The LDL was taken as the 1.024-
1.050 fraction. Acetylation was performed by the method of
Basu et al. (10).
Labeling of acetylated LDL with I25INa
Acetylated-LDL was labeled with 125INa according to Bilheimer
et al. (11). The specific radioactivity was about 3.7 KBq/mg of
acetylated LDL protein. Protein was determined by the method
of Lowry et al. (12).
Acetylated LDL catabolism
Cells were incubated for 24 h in medium devoid of lipoproteins
(supplemented with 2% Ultroser G) in the absence or in the
presence of drugs. After 3 washes with a phosphate-buffered
solution pH 7.4, the catabolism of modified LDL was studied
according to Goldstein et al. (13), with 10 mg/1 125I-acetylated-
LDL. Results are expressed in ng 125I-acetylated LDL per mg
of cellular protein.
Labeling of acetylated LDL with cholesteryl lin-
oleate
[3H]cholesteryl linoleate was incorporated into acetylated LDL
by the technique of Friedman et al. (14), using dimethylsulph-
oxide. The specific radioactivity was about 2 MBq/mg of LDL
protein.
Oleic acid incorporation into cholesteryl ester and
triacylglycerols
Cells were incubated for 24 h in Dulbecco's MEM medium
supplemented with 2% Ultroser G and 50 mg/1 acetylated LDL
for induction of the acylcoenzyme A : cholesterol-O-acyltrans-
ferase activity, in the presence or in the absence of trifluoper-
azine or chlorpromazine at the concentrations indicated. [1-
14C]oleic acid 37MBq/l was then added and incubation further
performed 4 h at 37 °C. Cells were washed 4 times with a
phosphate-buffered solution pH 7.4, harvested with rubber
policemen, and centrifuged; lipid analysis was performed by
thin layer chromatography (15). Results were expressed as pmol
of precursor incorporated per mg of cell protein.
Acylcoenzyme A : cholesterol-O-acyltransferase ac-
tivity
Acylcoenzyme A : cholesterol-O-acyltransferase activity was
measured according to Brown et al. (16), in two different sys-
tems:
1. sonicated homogenates of cells preincubated for 24 h in
medium containing 2% Ultroser G + acetylated LDL 50 mg/1
in the absence or in the presence of drugs, or
2. homogenates of untreated cells preincubated 30 minutes at
37 °C with gentle shaking with trifluoperazine or chlorproma-
zine just before the measurement of acylcoenzyme A : choles-
terol-O-acyltransferase activity. Each assay contained 100 μg
of protein, sodium phosphate buffer 0.1 mol/1 pH 7.4, MgCl2
5 mmol/1, bovine serum albumin 0.2 g/1, [l-14C]oleoyl coenzyme
A (3.7 KBq) and unlabeled oleoyl-coenzyme A (final concen-
tration 10 μπιοΙ/1). The final incubation volume was 100 μΐ.
The reaction was carried put for 5 minutes at 37 °C and stopped
on ice. An aliquot of the incubation mixture was then put on
a silica gel plate, and neutral lipids were separated by thin layer
chromatography as described above. Spots corresponding to
cholesteryl ester were cut out and the radioactivity was counted
by liquid scintillation. Acylcoenzyme A : cholesteroUO-acyl-
transferase activity was expressed as nmol/h · mg of cell protein.
Metabolism of cholesteryl linoleate-labeled LDL
Cells were preincubated for 24 h in Dulbecco's MEM medium
supplemented with foetal calf serum, volume fraction 0.1, in
the absence or in the presence of trifluoperazine or chlorprom-
azine 10 μπιοΐ/ΐ. Acetylated LDL labeled with [3H]cholesteryl
linoleate was then added at a concentration of 10 mg/1. After
a further 24 h incubation at 37 °C, cells were washed 4 times
with a phosphate-buffered solution pH 7.4, harvested with
rubber policemen, and centrifuged; lipid analysis was performed
on aliquots of the cell suspension after direct application to
silica gel plates as previously described (15). The solvent system
was hexane/diethylether/acetic acid 70/30/2 (by vol.). After
autoradiography, lipids were identified by comparison with
purified standards (Sigma). Spots corresponding to cholesterol
and cholesteryl esters were cut out and their radioactivity meas-
ured by liquid scintillation in an Intertechnique instrument.
Results are expressed in fmol of [3H]cholesterol per mg of cell
protein.
Results
Table 1 presents the effect of trifluoperazine and
chlorpromazine on [14C]oleic acid incorporation into
cholesteryl esters and triacylglycerols by J 774 cells.
A dose-dependent decrease in cholesterol esterifica-
tion was observed; in the preserve of 10 μπιοΙ/1 tri-
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Tab. 1. Effect of trifluoperazine and chlorpromazine on
[HC]oleic acid incorporation into cholesteryl esters and
triacylglycerols. Cells were preincubated for 24 h in
Dulbecco's MEM medium supplemented with 2% Ul-
troser G and acetylated LDL 50 mg/1, in the absence
or in the presence of the drugs. [14C]-oleic acid was then
added (37 MBq/1) and incubation further performed
for 4 h at 37 PC before lipid analysis. Results are ex-
pressed as pmol of oleic acid incorporated per mg of
cell protein (means of 4 experimental values ± S. D.).
Addition
(μηιοΐ/ΐ)
None
Trifluoperazine
1
5
10
Chlorpromazine
1
5
10
Oleic acid incorpotiation into
cholesteryl esters
2590 ± 350
2020 + 275*
1320 + 180***
730 ± 115***
2200 + 280
1805 ± 234*
910 + 145***
triacylglycerols
1150 ± 168
1980 ± 175
1220 + 155
1375 ± 152
980 ± 160
1085 + 142
1280 ± 180
*: ρ < 0.05; ***: ρ < 0.001 by the Student's t-test.
Tab. 2. Effect of trifluoperazine and chlorpromazine on acyl-
coenzyme A : cholesterol-O-acyltransferase activity of
J 774 maerophages. Cells were preincubated for 24 h in
the absence or in the presence of drugs as specified in
the legend to tab. 1. After 3 washes, cells were harvested
with rubber policemen and acylcoenzyme A : choles-
terol-O-acyltransferase activity was measured on cell
homogenates over a period of 5 minutes at 37 °C.
Results are expressed in nmol/h · mg protein (means of
4 experimental values ± S. D.).
Addition
(μτηοΐ/ΐ)
Acylcoenzyme A : cholesterol-Oacyl-
transferase activity (nmol/h · mg protein)
None 11.6 ± 2.2 (100%)
Trifluoperazine
1
5
10
Chlorpromazine
1
5
10
8.0 ± 1.5
4.5 ± 0.9
1.9 ± 0.4
9.3 ± 1.8
5.1 ± 1.5
2.4 + 0.6
(69%)*
(39%)***
(16%)***
(80%)
(44%)***
(21%)***
*: p < 0.05; ***: ρ < 0.001 by the Student's t-test.
fluoperazine or chlorpromaziiie, the decrease was
about 70% or 65%, respectively. [14C]oleic acid in-
corporation into triacylglycerols, taken as an internal
control, was not significantly affected.
Table 2 shows that a 24 h preincubation of J 774 cells
with trifluoperazine or chlorpromazine resulted in a
marked reduction of the acylcoenzyme A: cholesterol-
O-acyltransferase activity further measured in vitro.
A dose-dependent inhibition was observed, with
about 60% reduction at 5 μτηιηοΐ/ΐ, and 80% decrease
at 10 μηιηιο1/1, in either trifluoperazine-treated or
chlorpromazine-treated cells.
From these results, it is concluded that phenothiazines
either directly inhibit acylcoenzyme A : cholesterol-
O-acyltransferase, or/and decrease its activity indi-
rectly by affecting acetylated LDL metabolism, since
it is known that the acylcoenzyme A : cholesterol-O-
acyltransferase activity of maerophages is highly de-
pendent on the uptake and degradation of modified
LDL (2, 3). In order to investigate these possibilities,
we further studied the effect of phenothiazines on
acetylated LDL catabolism by J 774 cells. Table 3
shows that both trifluoperazine and chlorpromazine
decreased [125I]acetylated LDL degradation by J 774
cells, with about 60% and 55% reduction for trifluo-
perazine and chlorpromazine (10 μιηοΐ/ΐ), respectively.
Concomitantly, the intracellular radioactivity, corre-
sponding to undegraded acetylated LDL, was mark-
edly increased in both cases. The total radioactivity
(intracellular + degraded) remained unchanged, in-
dicating that the increased intracellular radioactivity
merely reflected the reduced lysosomal degradation.
We also investigated the possibility of a direct inhi-
bition of the acylcoenzyme A : cholesterol-O-acyl-
transferase activity by phenothiazines, in experiments
performed with homogenates of untreated J 774 cells
submitted to a short in vitro preincubation at 37 °C
in the presence of the drugs. Table 4 shows that under
these conditions, chlorpromazine and trifluoperazine
also decreased the acylcoenzyme A : cholesterol-O-
acyltransferase activity, although higher concentra-
Tab. 3. Effect of trifluoperazine and chlorpromazine on ace-
tylated LDL catabolism by J 774 cells. Ceils were prein-
cubated for 24 h with drugs, then washed and further
incubated 4 h at 37 °C with [125qacetylated LDL 10
mg/1. Results are expressed in ng [125I]acetylated LDL
per mg cellular protein (means of 3 experimental values
±S.D.).
Addition
(μπιοΐ/ΐ)
None
Trifluoperazine
1
5
10
Chlorpromazine
1
5
10
Intracellular
3440 ± 520
4200 + 475*
6190 + 470**
7200 ± 840***
3880 ± 265
5400 + 600**
6800 + 810***
Degraded
5200 ± 800
3860 ± 330*
3120 + 410**
2190 ± 270***
4240 ±510
3780 ± 455*
2430 ± 340***
*: p < 0.05; **: p < 0.01; ***: ρ < 0.001 by the Studenfs
t-test.
J. Clin. Chem. Clin. Biochem. / Vol. 26,1988 / No. 11
676 Houtia et al.: Phenothiazines inhibit cholesteryl ester formation
Tab. 4. Effect of short term in vitro preincubation of J 774 cell
homogenates with trifluoperazine or chlorpromazine on
acylcoenzyme A: cholesterol-O-acyltransferase activity.
Homogenates of J 774 cells pretreated for 24 h in me-
dium supplemented with Ultroser G 2% -I- acetylated
LDL 50 rag/1 were incubated 30 minutes at 37 °C with
gentle shaking in the absence or in the presence of the
drugs; acylcoenzyme A : cholesterol-O-acyltransferase
activity was then measured over a period of 5 minutes
at 37 °C. Enzyme activity is expressed in nmol/h · mg
of cellular proteins (means of 3 experimental values
+ S.D.).
Addition
(μηιοΐ/ΐ)
None
Trifluoperazine
1
5
10
Chlorpromazine
1
5
10
*: ρ < 0.05; **: ρ
t-test.
Acylcoenzyme A : cholesterol-O-acyl-
transferase activity (nmol/h · mg protein)
12.4± 1.8 (100%)
9.9 + 1.3 (80%)*
6.2 + 0.8 (50%)***
1.9 ±0.3 (15%)***
11.2 Η- 1.5 (90%)
6.7 + 1.1 (56%)**
2.7 ± 0.4 (22%)***
< 0.01; ***: ρ < 0.001 by the Student's
Tab. 5. Effect of trifluoperazine and chlorpromazine on
[3H]cholesteryl ester metabolism by J 774 monocyte-
like cells. Cells were preincubated for 24 h with or
without drugs 10 μιηοΐ/ΐ in Dulbecco's MEM medium
before addition of 10 mg/1 of [3H]cholesteryl linoleate-
loaded acetylated LDL. After a further 24 h incubation,
cells were extensively washed, harvested and lipid anal-
ysis performed as described in materials and methods.
Results are expressed in fmol/mg of cellular protein
(means of 4 experimental values ± S. C.).
Effector
(μιηοΐ/ΐ)
Radioactivity recovered in
free cholesteryl
cholesterol esters
Total
None
Trifluoperazine
10
460 ± 65 265 + ± 38 725 (100%)
310 ± 52* 33 ± 8*** 343 (47%)
Chlorpromazine
10 370 ±70 48 ± 13*** 418 (58%)
*: ρ < 0.05; ***: ρ < 0.001 by the Studenfs t-test.
tions of drugs must be utilized to observe a significant
effect: about 50% decrease was observed both for
chlorpromazine or trifluoperazine (100 μηιοΐ/ΐ), and
about 80% decrease was noted at 500 μηιοΐ/ΐ.
It was also of interest to investigate the effects of
phenothiazines on the metabolism of exogenous chol-
steryl esters introduced into cells by means of the
scavenger receptor pathway. We thus loaded acety-
lated LDL with cholesteryl linoleate labelled in the
cholesterol moiety and measured the radioactivity
recovered in free and esterified cellular cholesterol
after a 24 h incubation of J 774 cells with radioactive
acetylated LDL. The results are shown in table 5.
Trifluoperazine or chlorpromazine (10 μιηοΐ/ΐ)
strongly decreased the radioactivity recovered in cho-
lesteryl esters after a 24 h incubation with cholesteryl
linoleate-labeled acetylated-LDL. It can be seen that
the radioactivity recovered in free cholesterol was less
affected, with about 20-30% decrease compared
with the control. The total radioactivity recovered in
cholesterol (free + esterified) was decreased about
50% and 40% in the presence of trifluoperazine or
chlorpromazine (10 μπιοΐ/ΐχ respectively.
Discussion
This work demonstrates that phenothiazines strongly
inhibit oleic acid incorporation into cholesteryl esters
and acyl coenzyme A : cholesterol-O-acyltransferase
activity in J 774 monocyte-like cells. This effect ap-
pears to involve at least two mechanisms: a reduction
of acetylated LDL degradation (tab. 3), and a direct
inhibition of the enzyme acyl coenzyme A : choles-
terol-O-acyltransferase (tab. 4). In previous studies,
Bell reported that chlorpromazine inhibited choles-
terol esterification in arterial tissue and isolated ar-
terial microsomes (8). Acylcoenzyme A : cholesterol-
O-acyltransferase activity of isolated arterial micro-
somes was diminished in vitro by about 50% in the
presence of 100 μπιοΐ/ΐ chlorpromazine and by more
than 95% at 1 mmol/1 (8). These values are close to
that found in our experiments. More recently, Stein
& Stein (17) demonstrated that verapamil, another
calcium antagonist drug, inhibited cholesterol esteri-
fication in the J 774 cell line. However, these authors
did not find a direct effect of this drug on the acyl-
coenzyme A : cholesterol-O-acyltransferase activity,
and concluded that this inhibition could be related to
an impaired lysosornal hydrolysis of exogenous cho-
lesteryl ester and a subsequent decrease in the delivery
of free cholesterol to the site of acylcoenzyme A :
cholesterol-O-acyltransferase regulation.
The inhibitory effect of phenothiazines on the deg-
radation of acetylated LDL by J 774 cells is probably
related to the antagonistic effect of these drugs on
calmodulin-dependent mechanisms. In previous stud-
ies, Van Berkel et al. demonstrated a reduction of
acetylated LDL catabolism by trifluoperazine in an-
other experimental system, the rat liver non-paren-
chymal cell (18). In fibroblasts, we also found a strong
inhibition of native LDL degradation by calmodulin
antagonists such as trifluoperazine-or calmidazolium
(5). These effects are probably dire to an interaction
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of the drugs with some cytoskeleton components in-
volved in the endocytic processes, leading to a de-
crease in acetylated LDL delivery to lysosomes.
The mechanism by which phenothiazines directly in-
hibit the acylcoenzyme A : cholesterol-O-acyltrans-
ferase activity is probably related to alterations in the
membrane ultrastructure, and especially in the phys-
ical state of membrane lipids: various amphiphilic
compounds exhibiting local anaesthetic properties are
able to inhibit acylcoenzyme A : cholesterol-O-acyl-
transferase activity (19). Interaction of amphiphilic
compounds with membrane phospholipids, with a
subsequent increase in membrane fluidity, has been
reported in several experimental systems (20, 21). As
acylcoenzyme A : cholesterol-O-acyltransferase ap-
pears to be very sensitive to alterations of its micro-
somal membrane microenvironment (22), it is likely
that the inhibition of this enzyme activity could be
related to the interaction of phenothiazines with cel-
lular membranes.
The dramatic reduction by chlorpromazine and tri-
fluoperazine of the re-esterification of cholesterol en-
tering via the acetylated LDL pathway is of particular
interest. This results in a strong reduction of the
radioactivity recovered in the cholesteryl ester frac-
tion, and also in a decrease of the total cell-bound
radioactivity (free + esterified cholesterol). This
might be due to a stimulation of cholesterol efflux
from the monocyte-macrophage cell, since the slow
calcium channel blocker, nifedipine, has been reported
to promote cholesterol efflux from mouse peritoneal
rnacrophages (23).
The inhibitory effect of phenothiazines on cholesterol
esterification has not yet been reported in the mono-
cyte-macrophages. This phenomenon may be of great
interest in view of the fact that cholesteryl ester ac-
cumulation is currently believed to be one of the main
features involved in the formation of atherosclerotic
lesions (1). Massive cholesteryl ester accumulation in
monocyte-derived rnacrophages is due to the non-
down-regulated uptake of LDL, probably modified
by oxidative processes (24). These modifications are
the result of a decreased turnover of the LDL in
subjects presenting a defect in the apolipoprotein B/E-
specific receptor pathway, which results in an in-
creased half-life of the LDL in plasma. It would
therefore be of interest to reduce cholesteryl ester
accumulation in monocyte-macrophages: this may be
an alternative way of preventing atherogenesis. At
present, the therapeutics of atherogenesis in hetero-
zygous subjects with familial hypercholesterolaemia
are mainly based on the induction of the apolipopro-
tein B/E receptor by inhibitors of cholesterol synthesis
such as mevinolin (25), and inhibitors of intestinal
bile acid reabsorption such as cholestyramine (26).
But it must be emphasized that such therapeutics only
result in a moderate increase in LDL catabolism by
the specific receptor pathway, and that they do not
act on the process directly involved in atherogenesis,
e. g. cholesteryl ester accumulation by macrophages.
Moreover, inhibitors of cholesterol synthesis evidently
fail to accelerate LDL turnover in homozygous sub-
jects with familial hypercholesterolaemia. In this case,
the only steps which can be influenced by therapeutic
agents are cholesterol synthesis and cholesteryl ester
accumulation by macrophages. The use of amphi-
philic cationic drugs especially designed for this pur-
pose may therefore have interesting therapeutic pos-
sibilities.
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